Evaluating a new treatment for schizophrenia using brain imaging techniques
A Translational and Neurocomputational Evaluation of a D1R Partial Agonist for Schizophrenia
This study is looking at a new medication that might help improve thinking skills in people with schizophrenia by affecting certain brain receptors, and it will use brain scans to find the best dose and see how it works for each person.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10248465 on NIH RePORTER |
What this research studies
This research investigates the effects of a new medication that partially activates dopamine D1 receptors, which may improve cognitive function in individuals with schizophrenia. By using advanced brain imaging techniques, the study aims to identify the optimal dosage and understand how this treatment affects brain activity related to working memory. Patients will be closely monitored to assess how well the medication works and to identify the best candidates for this therapy. The approach combines neuroscience with precision medicine to tailor treatment to individual needs.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with schizophrenia who may benefit from improved cognitive function.
Not a fit: Patients who do not have a diagnosis of schizophrenia or those who are not responsive to dopamine-related treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective treatment for schizophrenia that enhances cognitive function and reduces symptoms.
How similar studies have performed: Previous studies have shown promise in using dopamine receptor agonists for cognitive enhancement in schizophrenia, but this specific approach is novel in its precision medicine strategy.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Krystal, John H. — Yale University
- Study coordinator: Krystal, John H.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.